Notwithstanding any provisions of this part 5 to the contrary, and subject to any necessary federal authorization, the state board shall require a review for coverage of a new drug approved by the federal food and drug administration for a serious mental illness within ninety days after the approval of the drug.

Source: L. 2023: Entire section added, (HB 23-1130), ch. 394, p. 2356, § 3, effective August 7.